Haleon plc reports director share purchase

Published 02/05/2025, 15:34
Haleon plc reports director share purchase

Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, announced today that Asmita Dubey, an Independent (LON:IOG) Non-Executive Director and Person Discharging Managerial Responsibilities (PDMR), has purchased ordinary shares in the company. The transaction took place on the London Stock Exchange (LON:LSEG) (XLON) on Friday.

Dubey acquired a total of 15,424 ordinary shares at a price of £4.01 per share. This information is disclosed in accordance with the UK Market Abuse Regulation, which mandates public notification of transactions by PDMRs.

The purchase is a sign of confidence in the company from one of its directors, reflecting a personal investment in Haleon’s continued success. Haleon’s product portfolio includes well-known brands such as Advil, Centrum, and Sensodyne, covering a range of health categories from oral care to pain relief and vitamins.

This transaction is part of the standard regulatory filings required by the Securities Exchange Act of 1934, which ensures transparency in the financial activities of corporate insiders. The report is signed by Amanda Mellor, Company Secretary of Haleon plc, confirming the details of the transaction.

For more information on Haleon’s product offerings and initiatives, interested parties can visit their official website. The disclosure of this shareholding aligns with Haleon’s commitment to corporate transparency and governance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.